Vertex stops VX-745 trials
Executive Summary
Vertex will not proceed with enrollment in the higher-dose cohort in Phase II trials with orally active p38 MAP kinase inhibitor VX-745 following the finding of adverse effects within the central nervous system in one of two animal species receiving high-dose exposure. The company will move ahead on second-generation p38 inhibitors VX-702 and VX-850 for treatment of inflammatory disease, initiating clinical studies with one or both of the candidates in the first half of 2002
|
Vertex will not proceed with enrollment in the higher-dose cohort in Phase II trials with orally active p38 MAP kinase inhibitor VX-745 following the finding of adverse effects within the central nervous system in one of two animal species receiving high-dose exposure. The company will move ahead on second-generation p38 inhibitors VX-702 and VX-850 for treatment of inflammatory disease, initiating clinical studies with one or both of the candidates in the first half of 2002. |